Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects
11 C-RO-963, 11 C-RO-643, and 18 F-RO-948 (previously referred to as 11 C-RO6924963, 11 C-RO6931643, and 18 F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluatio...
Gespeichert in:
| Veröffentlicht in: | The Journal of nuclear medicine (1978) 2018-12, Vol.59 (12), p.1869-1876 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1876 |
|---|---|
| container_issue | 12 |
| container_start_page | 1869 |
| container_title | The Journal of nuclear medicine (1978) |
| container_volume | 59 |
| creator | Wong, Dean F Comley, Robert A Kuwabara, Hiroto Rosenberg, Paul B Resnick, Susan M Ostrowitzki, Susanne Vozzi, Cristina Boess, Frank Oh, Esther Lyketsos, Constantine G Honer, Michael Gobbi, Luca Klein, Gregory George, Noble Gapasin, Lorena Kitzmiller, Kelly Roberts, Josh Sevigny, Jeff Nandi, Ayon Brasic, James Mishra, Chakradhar Thambisetty, Madhav Mogekar, Abhay Mathur, Anil Albert, Marilyn Dannals, Robert F Borroni, Edilio |
| description | 11
C-RO-963,
11
C-RO-643, and
18
F-RO-948 (previously referred to as
11
C-RO6924963,
11
C-RO6931643, and
18
F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers.
Methods:
Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of
11
C-RO-963,
11
C-RO-643, or
18
F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with
18
F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated
18
F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with
18
F-RO-948.
Results:
In younger controls, SUV
peak
was observed in the temporal lobe with values of approximately 3.0 for
11
C-RO-963, 1.5 for
11
C-RO-643, and 3.5 for
18
F-RO-948. Over all brain regions and subjects, the trend was for
18
F-RO-948 to have the highest SUV
peak
, followed by
11
C-RO-963 and then
11
C-RO-643. Regional analysis of SUV ratio and total distribution volume for
11
C-RO-643 and
18
F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that
11
C-RO-643 had lower brain entry than either
11
C-RO-963 or
18
F-RO-948 and that
18
F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on
18
F-RO-948. Both voxelwise and region-based analysis of
18
F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA,
F
(1,21)
= 45,
P
< 10
−5
). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of
P
< 0.001, cluster size > 50).
Conclusion:
18
F-RO-948 demonstrates characteristics superior to
11
C-RO-643 and
1 |
| doi_str_mv | 10.2967/jnumed.118.209916 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6278896</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2035245938</sourcerecordid><originalsourceid>FETCH-LOGICAL-j1976-65b46273a862c5fa8499609ce5e8351013a08d8c60608fd4610dc5dd980961f23</originalsourceid><addsrcrecordid>eNpVkMtKw0AUhgdRtFYfwN0sXZg6l8zJmY0gwRsUC7Wuw3QyMVOSTM1FsK_gSxu0CK7Oz_l_vnMh5IKzmdCQXG-aoXb5jHOcCaY1hwMy4UqqSAEkh2TCOPBIKaZOyGnXbRhjgIjH5EToRKDiekK-0tK0xvau9TvT-9DQUFBJn8OHq-jKDHRpch-2Y6g21g29t6bqrijnabRcRBrkn4Z41KbJKcf7Hy_GK-ob-uhM1ZefNA1N34aq-8mM_dtqVzpfu5a-DOuNs313Ro6Kke7O93VKXu_vVuljNF88PKW382jDdQIRqHUMIpEGQVhVGIy1BqatUw6l4oxLwzBHCwwYFnkMnOVW5blGpoEXQk7JzS93O6zH_1k3LmaqbNv62rSfWTA---80vszewkc2TkUcb56Syz2gDe-D6_qs9p11VWUaF4YuE0wqESstUX4DGG18OA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2035245938</pqid></control><display><type>article</type><title>Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Wong, Dean F ; Comley, Robert A ; Kuwabara, Hiroto ; Rosenberg, Paul B ; Resnick, Susan M ; Ostrowitzki, Susanne ; Vozzi, Cristina ; Boess, Frank ; Oh, Esther ; Lyketsos, Constantine G ; Honer, Michael ; Gobbi, Luca ; Klein, Gregory ; George, Noble ; Gapasin, Lorena ; Kitzmiller, Kelly ; Roberts, Josh ; Sevigny, Jeff ; Nandi, Ayon ; Brasic, James ; Mishra, Chakradhar ; Thambisetty, Madhav ; Mogekar, Abhay ; Mathur, Anil ; Albert, Marilyn ; Dannals, Robert F ; Borroni, Edilio</creator><creatorcontrib>Wong, Dean F ; Comley, Robert A ; Kuwabara, Hiroto ; Rosenberg, Paul B ; Resnick, Susan M ; Ostrowitzki, Susanne ; Vozzi, Cristina ; Boess, Frank ; Oh, Esther ; Lyketsos, Constantine G ; Honer, Michael ; Gobbi, Luca ; Klein, Gregory ; George, Noble ; Gapasin, Lorena ; Kitzmiller, Kelly ; Roberts, Josh ; Sevigny, Jeff ; Nandi, Ayon ; Brasic, James ; Mishra, Chakradhar ; Thambisetty, Madhav ; Mogekar, Abhay ; Mathur, Anil ; Albert, Marilyn ; Dannals, Robert F ; Borroni, Edilio</creatorcontrib><description>11
C-RO-963,
11
C-RO-643, and
18
F-RO-948 (previously referred to as
11
C-RO6924963,
11
C-RO6931643, and
18
F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers.
Methods:
Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of
11
C-RO-963,
11
C-RO-643, or
18
F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with
18
F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated
18
F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with
18
F-RO-948.
Results:
In younger controls, SUV
peak
was observed in the temporal lobe with values of approximately 3.0 for
11
C-RO-963, 1.5 for
11
C-RO-643, and 3.5 for
18
F-RO-948. Over all brain regions and subjects, the trend was for
18
F-RO-948 to have the highest SUV
peak
, followed by
11
C-RO-963 and then
11
C-RO-643. Regional analysis of SUV ratio and total distribution volume for
11
C-RO-643 and
18
F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that
11
C-RO-643 had lower brain entry than either
11
C-RO-963 or
18
F-RO-948 and that
18
F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on
18
F-RO-948. Both voxelwise and region-based analysis of
18
F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA,
F
(1,21)
= 45,
P
< 10
−5
). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of
P
< 0.001, cluster size > 50).
Conclusion:
18
F-RO-948 demonstrates characteristics superior to
11
C-RO-643 and
11
C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of
18
F-RO-948 compare favorably with other existing tau PET tracers.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>DOI: 10.2967/jnumed.118.209916</identifier><identifier>PMID: 29728519</identifier><language>eng</language><publisher>Society of Nuclear Medicine</publisher><subject>Neurology</subject><ispartof>The Journal of nuclear medicine (1978), 2018-12, Vol.59 (12), p.1869-1876</ispartof><rights>2018 by the Society of Nuclear Medicine and Molecular Imaging. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Wong, Dean F</creatorcontrib><creatorcontrib>Comley, Robert A</creatorcontrib><creatorcontrib>Kuwabara, Hiroto</creatorcontrib><creatorcontrib>Rosenberg, Paul B</creatorcontrib><creatorcontrib>Resnick, Susan M</creatorcontrib><creatorcontrib>Ostrowitzki, Susanne</creatorcontrib><creatorcontrib>Vozzi, Cristina</creatorcontrib><creatorcontrib>Boess, Frank</creatorcontrib><creatorcontrib>Oh, Esther</creatorcontrib><creatorcontrib>Lyketsos, Constantine G</creatorcontrib><creatorcontrib>Honer, Michael</creatorcontrib><creatorcontrib>Gobbi, Luca</creatorcontrib><creatorcontrib>Klein, Gregory</creatorcontrib><creatorcontrib>George, Noble</creatorcontrib><creatorcontrib>Gapasin, Lorena</creatorcontrib><creatorcontrib>Kitzmiller, Kelly</creatorcontrib><creatorcontrib>Roberts, Josh</creatorcontrib><creatorcontrib>Sevigny, Jeff</creatorcontrib><creatorcontrib>Nandi, Ayon</creatorcontrib><creatorcontrib>Brasic, James</creatorcontrib><creatorcontrib>Mishra, Chakradhar</creatorcontrib><creatorcontrib>Thambisetty, Madhav</creatorcontrib><creatorcontrib>Mogekar, Abhay</creatorcontrib><creatorcontrib>Mathur, Anil</creatorcontrib><creatorcontrib>Albert, Marilyn</creatorcontrib><creatorcontrib>Dannals, Robert F</creatorcontrib><creatorcontrib>Borroni, Edilio</creatorcontrib><title>Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects</title><title>The Journal of nuclear medicine (1978)</title><description>11
C-RO-963,
11
C-RO-643, and
18
F-RO-948 (previously referred to as
11
C-RO6924963,
11
C-RO6931643, and
18
F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers.
Methods:
Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of
11
C-RO-963,
11
C-RO-643, or
18
F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with
18
F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated
18
F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with
18
F-RO-948.
Results:
In younger controls, SUV
peak
was observed in the temporal lobe with values of approximately 3.0 for
11
C-RO-963, 1.5 for
11
C-RO-643, and 3.5 for
18
F-RO-948. Over all brain regions and subjects, the trend was for
18
F-RO-948 to have the highest SUV
peak
, followed by
11
C-RO-963 and then
11
C-RO-643. Regional analysis of SUV ratio and total distribution volume for
11
C-RO-643 and
18
F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that
11
C-RO-643 had lower brain entry than either
11
C-RO-963 or
18
F-RO-948 and that
18
F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on
18
F-RO-948. Both voxelwise and region-based analysis of
18
F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA,
F
(1,21)
= 45,
P
< 10
−5
). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of
P
< 0.001, cluster size > 50).
Conclusion:
18
F-RO-948 demonstrates characteristics superior to
11
C-RO-643 and
11
C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of
18
F-RO-948 compare favorably with other existing tau PET tracers.</description><subject>Neurology</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVkMtKw0AUhgdRtFYfwN0sXZg6l8zJmY0gwRsUC7Wuw3QyMVOSTM1FsK_gSxu0CK7Oz_l_vnMh5IKzmdCQXG-aoXb5jHOcCaY1hwMy4UqqSAEkh2TCOPBIKaZOyGnXbRhjgIjH5EToRKDiekK-0tK0xvau9TvT-9DQUFBJn8OHq-jKDHRpch-2Y6g21g29t6bqrijnabRcRBrkn4Z41KbJKcf7Hy_GK-ob-uhM1ZefNA1N34aq-8mM_dtqVzpfu5a-DOuNs313Ro6Kke7O93VKXu_vVuljNF88PKW382jDdQIRqHUMIpEGQVhVGIy1BqatUw6l4oxLwzBHCwwYFnkMnOVW5blGpoEXQk7JzS93O6zH_1k3LmaqbNv62rSfWTA---80vszewkc2TkUcb56Syz2gDe-D6_qs9p11VWUaF4YuE0wqESstUX4DGG18OA</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Wong, Dean F</creator><creator>Comley, Robert A</creator><creator>Kuwabara, Hiroto</creator><creator>Rosenberg, Paul B</creator><creator>Resnick, Susan M</creator><creator>Ostrowitzki, Susanne</creator><creator>Vozzi, Cristina</creator><creator>Boess, Frank</creator><creator>Oh, Esther</creator><creator>Lyketsos, Constantine G</creator><creator>Honer, Michael</creator><creator>Gobbi, Luca</creator><creator>Klein, Gregory</creator><creator>George, Noble</creator><creator>Gapasin, Lorena</creator><creator>Kitzmiller, Kelly</creator><creator>Roberts, Josh</creator><creator>Sevigny, Jeff</creator><creator>Nandi, Ayon</creator><creator>Brasic, James</creator><creator>Mishra, Chakradhar</creator><creator>Thambisetty, Madhav</creator><creator>Mogekar, Abhay</creator><creator>Mathur, Anil</creator><creator>Albert, Marilyn</creator><creator>Dannals, Robert F</creator><creator>Borroni, Edilio</creator><general>Society of Nuclear Medicine</general><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181201</creationdate><title>Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects</title><author>Wong, Dean F ; Comley, Robert A ; Kuwabara, Hiroto ; Rosenberg, Paul B ; Resnick, Susan M ; Ostrowitzki, Susanne ; Vozzi, Cristina ; Boess, Frank ; Oh, Esther ; Lyketsos, Constantine G ; Honer, Michael ; Gobbi, Luca ; Klein, Gregory ; George, Noble ; Gapasin, Lorena ; Kitzmiller, Kelly ; Roberts, Josh ; Sevigny, Jeff ; Nandi, Ayon ; Brasic, James ; Mishra, Chakradhar ; Thambisetty, Madhav ; Mogekar, Abhay ; Mathur, Anil ; Albert, Marilyn ; Dannals, Robert F ; Borroni, Edilio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j1976-65b46273a862c5fa8499609ce5e8351013a08d8c60608fd4610dc5dd980961f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Neurology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wong, Dean F</creatorcontrib><creatorcontrib>Comley, Robert A</creatorcontrib><creatorcontrib>Kuwabara, Hiroto</creatorcontrib><creatorcontrib>Rosenberg, Paul B</creatorcontrib><creatorcontrib>Resnick, Susan M</creatorcontrib><creatorcontrib>Ostrowitzki, Susanne</creatorcontrib><creatorcontrib>Vozzi, Cristina</creatorcontrib><creatorcontrib>Boess, Frank</creatorcontrib><creatorcontrib>Oh, Esther</creatorcontrib><creatorcontrib>Lyketsos, Constantine G</creatorcontrib><creatorcontrib>Honer, Michael</creatorcontrib><creatorcontrib>Gobbi, Luca</creatorcontrib><creatorcontrib>Klein, Gregory</creatorcontrib><creatorcontrib>George, Noble</creatorcontrib><creatorcontrib>Gapasin, Lorena</creatorcontrib><creatorcontrib>Kitzmiller, Kelly</creatorcontrib><creatorcontrib>Roberts, Josh</creatorcontrib><creatorcontrib>Sevigny, Jeff</creatorcontrib><creatorcontrib>Nandi, Ayon</creatorcontrib><creatorcontrib>Brasic, James</creatorcontrib><creatorcontrib>Mishra, Chakradhar</creatorcontrib><creatorcontrib>Thambisetty, Madhav</creatorcontrib><creatorcontrib>Mogekar, Abhay</creatorcontrib><creatorcontrib>Mathur, Anil</creatorcontrib><creatorcontrib>Albert, Marilyn</creatorcontrib><creatorcontrib>Dannals, Robert F</creatorcontrib><creatorcontrib>Borroni, Edilio</creatorcontrib><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, Dean F</au><au>Comley, Robert A</au><au>Kuwabara, Hiroto</au><au>Rosenberg, Paul B</au><au>Resnick, Susan M</au><au>Ostrowitzki, Susanne</au><au>Vozzi, Cristina</au><au>Boess, Frank</au><au>Oh, Esther</au><au>Lyketsos, Constantine G</au><au>Honer, Michael</au><au>Gobbi, Luca</au><au>Klein, Gregory</au><au>George, Noble</au><au>Gapasin, Lorena</au><au>Kitzmiller, Kelly</au><au>Roberts, Josh</au><au>Sevigny, Jeff</au><au>Nandi, Ayon</au><au>Brasic, James</au><au>Mishra, Chakradhar</au><au>Thambisetty, Madhav</au><au>Mogekar, Abhay</au><au>Mathur, Anil</au><au>Albert, Marilyn</au><au>Dannals, Robert F</au><au>Borroni, Edilio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2018-12-01</date><risdate>2018</risdate><volume>59</volume><issue>12</issue><spage>1869</spage><epage>1876</epage><pages>1869-1876</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract>11
C-RO-963,
11
C-RO-643, and
18
F-RO-948 (previously referred to as
11
C-RO6924963,
11
C-RO6931643, and
18
F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers.
Methods:
Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of
11
C-RO-963,
11
C-RO-643, or
18
F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with
18
F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated
18
F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with
18
F-RO-948.
Results:
In younger controls, SUV
peak
was observed in the temporal lobe with values of approximately 3.0 for
11
C-RO-963, 1.5 for
11
C-RO-643, and 3.5 for
18
F-RO-948. Over all brain regions and subjects, the trend was for
18
F-RO-948 to have the highest SUV
peak
, followed by
11
C-RO-963 and then
11
C-RO-643. Regional analysis of SUV ratio and total distribution volume for
11
C-RO-643 and
18
F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that
11
C-RO-643 had lower brain entry than either
11
C-RO-963 or
18
F-RO-948 and that
18
F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on
18
F-RO-948. Both voxelwise and region-based analysis of
18
F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA,
F
(1,21)
= 45,
P
< 10
−5
). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of
P
< 0.001, cluster size > 50).
Conclusion:
18
F-RO-948 demonstrates characteristics superior to
11
C-RO-643 and
11
C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of
18
F-RO-948 compare favorably with other existing tau PET tracers.</abstract><pub>Society of Nuclear Medicine</pub><pmid>29728519</pmid><doi>10.2967/jnumed.118.209916</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | The Journal of nuclear medicine (1978), 2018-12, Vol.59 (12), p.1869-1876 |
| issn | 0161-5505 1535-5667 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6278896 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Neurology |
| title | Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A08%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%203%20Novel%20Tau%20Radiopharmaceuticals,%2011C-RO-963,%2011C-RO-643,%20and%2018F-RO-948,%20in%20Healthy%20Controls%20and%20in%20Alzheimer%20Subjects&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Wong,%20Dean%20F&rft.date=2018-12-01&rft.volume=59&rft.issue=12&rft.spage=1869&rft.epage=1876&rft.pages=1869-1876&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.118.209916&rft_dat=%3Cproquest_pubme%3E2035245938%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2035245938&rft_id=info:pmid/29728519&rfr_iscdi=true |